[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

December 29, 2016
Viewpoint

The High Cost of New Cancer Therapies—A Challenge of Inequality for All Countries

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.6335

This Viewpoint describes the high cost of new cancer therapies, making comparisons to the early years of the AIDS epidemic, when many patients in low-resource countries died because of the initial high cost of HIV medications.

Cancer Care Chronicles

Processing Death

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5105
Original Investigation

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.4166

This analysis of health technology assessment reports examines the overall survival, quality of life, and safety benefits associated with recently licensed cancer medicines.

Second Opinions From Medical Oncologists for Early-Stage Breast CancerPrevalence, Correlates, and Consequences

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5652

This study investigates the patterns and correlates of second opinion use and the effect on chemotherapy decisions.

Brief Report

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5592

This case-control study analyzed the entire coding region of the FANCM gene to find its association with breast and ovarian cancer risk.

Special Communication

A Standard Set of Value-Based Patient-Centered Outcomes for Breast CancerThe International Consortium for Health Outcomes Measurement (ICHOM) Initiative

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.4851

This Special Communication examines the development of a standard set of value-based patient-centered outcomes for breast cancer.

Review

Making Molecular Imaging a Clinical Tool for Precision OncologyA Review

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5084

This review discusses the advantages and disadvantages of molecular imaging for use in oncologic clinical trials as well as clinical practice settings.

Research Letter

Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States

Abstract Full Text
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5465

This population-based study assesses the effect of the decline in prostate-specific antigen screening and incidence on prostate cancer presentation.

Editor's Note

Determining Penetration of Prostate-Specific Antigen Screening Recommendations

Abstract Full Text
free access
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5978
December 22, 2016
Viewpoint

Surgery for Patients With Rectal Cancer—Time to Listen to the Patients and Recognize Reality

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5380

This Viewpoint argues that surgery is not necessary for all patients with rectal cancer who respond to chemoradiation.

Evidence in Favor of Standard Surgical Treatment for Rectal Cancer

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5397

This Viewpoint argues that that it is premature to practice selective withdrawal of surgery based on the curative contribution of surgery, the lack of reliable predictive biomarkers, and the scarcity of solid evidence in support of this practice.

Original Investigation

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers A Secondary Analysis of 2 Randomized Clinical Trials

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5469

This secondary analysis of 2 randomized clinical trials examines the association of DNA mismatch repair status and somatic gene mutations in the primary tumor of patients with stage III colon cancer treated with adjuvant chemotherapy.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell CancerA Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5478

This secondary analysis of a randomized clinical trial examines whether a germline mutation in a microRNA-binding site in KRAS is a predictive biomarker of cetuximab response and altered immunity following radiotherapy and cisplatin treatment for head and neck squamous cell cancer.

Brief Report

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5598

This study examined whether African American women are more susceptable to triple-negative breast cancer.

Invited Commentary

Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal CancerWhat Happens at Relapse?

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5463

The KRAS Variant as a Predictive Biomarker of Cetuximab Response in Head and Neck Cancer

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5686
JAMA Oncology Clinical Challenge

A Rapidly Expanding Scalp Mass

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5090

A woman in her 80s presented with a 2-week history of an enlarging left parietal scalp mass that continued to enlarge. She subsequently developed progressive generalized weakness, slowed speech, and focal right-handed weakness. What is your diagnosis?

Comment & Response

The Optimal Body Mass Index Range for Patients With Colorectal Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5280

The Optimal Body Mass Index Range for Patients With Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5303
December 15, 2016
Editorial

Universal Genetic Testing for Younger Patients With Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5193
Original Investigation

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5194

This cohort study examines the frequency and spectrum of cancer susceptibility gene mutations among patients with early-onset colorectal cancer.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior TherapySWOG S1115 Study Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5383

This phase 2 randomized clinical trial compares selumetinib and MK-2206 vs modified FOLFOX chemotherapy in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed.

Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal AdenomasA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5917

This randomized clinical trial investigates whether common variants in vitamin D and calcium pathway genes modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence.

Review

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung CancerA Systematic Review

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.4280

This systematic review compares outcomes and toxic effects between thoracic radiation with either cisplatin-etoposide or carboplatin-paclitaxel for patients with stage III non–small-cell lung cancer.

JAMA Oncology Clinical Challenge

An Aggressive Mandibular Mass

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5648

A woman in her 70s presented with progressive supraclavicular, facial, and mandibular swelling of 3 months’ duration; a fixed mass throughout the left preauricular space; and a right supraclavicular mass. What is your diagnosis?

Research Letter

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.4983

This study compares reports from 2 next-generation sequencing tests to determine the level of concordance between platforms.

Comment & Response

Lymphoma and Pregnancy—Reply

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.4848

Lymphoma and Pregnancy

Abstract Full Text
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.5290
December 8, 2016
Editorial

Human Papillomavirus–Associated Oropharyngeal CancerNot Just White Men Anymore

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.3510
Original Investigation

Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.3067

This cohort study explores the role of human papillomavirus status in patients with head and neck squamous cell cancer, stratified by race/ethnicity, sex, and oropharyngeal squamous cell carcinoma vs nonoropharyngeal head and neck squamous cell carcinoma.

Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.4500

This population-based study of patients with head and neck cancer investigates whether immunologic response to human papillomavirus 16 is associated with patient survival across anatomic sites, independent of smoking and drinking history.

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck CarcinomaA Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.4510

This randomized clinical trial of patients with locoregionally advanced squamous cell carcinoma of the head and neck compared the effect of accelerated-fractionation radiotherapy (RT) plus the anti–epidermal growth factor receptor antibody panitumumab vs standard-fractionation RT plus high-dose cisplatin on progression-free survival.

Research Letter

Odontoma in a 255-Million-Year-Old Mammalian Forebear

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.5417

This study describes cancer in a 255-million-year-old mammalian forebear and comments on the implications for establishing the phylogenetic and physiologic conditions under which such pathologic conditions first arose.

Comment & Response

Advances in the Decision to Image or Not to Image—Reply

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.4849

Advances in the Decision to Image or Not to Image

Abstract Full Text
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.5061
JAMA Oncology Patient Page

Novel Precision Medicine Trial DesignsUmbrellas and Baskets

Abstract Full Text
free access
JAMA Oncol. Published online December 8, 2016. doi:10.1001/jamaoncol.2016.5299
December 7, 2016
Brief Report

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

Abstract Full Text
JAMA Oncol. Published online December 7, 2016. doi:10.1001/jamaoncol.2016.5630

This study attempts to determine whether there are intrinsic subtype differences between primary breast cancer tumors and matched brain metastases (BrM) and to uncover BrM-acquired alterations that are clinically actionable.

December 3, 2016
Special Communication

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015A Systematic Analysis for the Global Burden of Disease Study

Abstract Full Text
JAMA Oncol. Published online December 3, 2016. doi:10.1001/jamaoncol.2016.5688

Using the methodology and data sources of the Global Burden of Disease study, this systematic analysis estimates mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life-years for 32 cancers in 195 countries and territories from 1990 to 2015.

December 1, 2016
Viewpoint

Outcome Measurement in Value-Based Payments

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5375

This Viewpoint discusses quality measures for colorectal, breast, prostate, and lung cancer.

Cancer Care Chronicles

Reimagining the Initial Office Visit

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.4988
Original Investigation

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell CancerThe ROPETAR Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5202

This randomized clinical trial compares the effects of an 8-week rotating treatment schedule with pazopanib and everolimus vs continuous pazopanibon disease progression in patients with metastatic clear cell renal cell cancer.

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal AdenocarcinomaThe METGastric Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5580

This randomized clinical trial assesses whether the addition of onartuzumab, a MET antibody, to first-line fluorouracil, leucovorin, and oxaliplatin therapy improves efficacy outcomes in HER2-negative, MET-positive gastroesophageal adenocarcinoma.

Review

Axillary Nodal Management Following Neoadjuvant ChemotherapyA Review

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.4163

This review discusses the controversies and unanswered questions regarding axillary management in patients receiving neoadjuvant chemotherapy for breast cancer.

Research Letter

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5487

This study examines the association of malignant mesothelioma with exposure to asbestos among individuals in Eastern China.

Comment & Response

Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis—Reply

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5279

Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis

Abstract Full Text
JAMA Oncol. Published online December 1, 2016. doi:10.1001/jamaoncol.2016.5293
×